Annual CFF
$391.82 M
+$212.87 M+118.95%
December 31, 2024
Summary
- As of March 12, 2025, KROS annual cash flow from financing activities is $391.82 million, with the most recent change of +$212.87 million (+118.95%) on December 31, 2024.
- During the last 3 years, KROS annual CFF has risen by +$363.27 million (+1272.40%).
- KROS annual CFF is now at all-time high.
Performance
KROS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$75.54 M
-$80.40 M-51.56%
December 31, 2024
Summary
- As of March 12, 2025, KROS quarterly cash flow from financing activities is $75.54 million, with the most recent change of -$80.40 million (-51.56%) on December 31, 2024.
- Over the past year, KROS quarterly CFF has stayed the same.
- KROS quarterly CFF is now -51.82% below its all-time high of $156.80 million, reached on March 31, 2024.
Performance
KROS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$391.82 M
+$6.29 M+1.63%
December 31, 2024
Summary
- As of March 12, 2025, KROS TTM cash flow from financing activities is $391.82 million, with the most recent change of +$6.29 million (+1.63%) on December 31, 2024.
- Over the past year, KROS TTM CFF has stayed the same.
- KROS TTM CFF is now at all-time high.
Performance
KROS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
KROS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +119.0% | 0.0% | 0.0% |
| 3 y3 years | +1272.4% | +165.8% | +1272.4% |
| 5 y5 years | +10000.0% | +10000.0% | +10000.0% |
KROS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +1272.4% | -51.8% | >+9999.0% | at high | +1272.4% |
| 5 y | 5-year | at high | >+9999.0% | -51.8% | >+9999.0% | at high | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -51.8% | -100.0% | at high | -100.0% |
Keros Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $391.82 M(+118.9%) | $75.54 M(-51.6%) | $391.82 M(+1.6%) |
| Sep 2024 | - | $155.94 M(+4316.4%) | $385.53 M(+67.7%) |
| Jun 2024 | - | $3.53 M(-97.7%) | $229.87 M(+0.8%) |
| Mar 2024 | - | $156.80 M(+126.4%) | $228.08 M(+27.5%) |
| Dec 2023 | $178.96 M(+48.7%) | $69.25 M(>+9900.0%) | $178.96 M(+4.6%) |
| Sep 2023 | - | $284.00 K(-83.7%) | $171.12 M(-22.0%) |
| Jun 2023 | - | $1.74 M(-98.4%) | $219.42 M(-3.7%) |
| Mar 2023 | - | $107.68 M(+75.3%) | $227.87 M(+89.4%) |
| Dec 2022 | $120.31 M(+321.4%) | $61.42 M(+26.4%) | $120.31 M(+37.8%) |
| Sep 2022 | - | $48.58 M(+376.7%) | $87.31 M(+125.2%) |
| Jun 2022 | - | $10.19 M(+8537.3%) | $38.76 M(+35.4%) |
| Mar 2022 | - | $118.00 K(-99.6%) | $28.63 M(+0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $28.55 M(-90.4%) | $28.42 M(>+9900.0%) | $28.55 M(-79.6%) |
| Sep 2021 | - | $35.00 K(-38.6%) | $140.25 M(+0.0%) |
| Jun 2021 | - | $57.00 K(+35.7%) | $140.22 M(-41.6%) |
| Mar 2021 | - | $42.00 K(-100.0%) | $240.29 M(-18.8%) |
| Dec 2020 | $296.04 M(>+9900.0%) | $140.12 M(>+9900.0%) | $296.04 M(+89.9%) |
| Sep 2020 | - | $9000.00(-100.0%) | $155.93 M(+0.0%) |
| Jun 2020 | - | $100.12 M(+79.5%) | $155.93 M(+179.4%) |
| Mar 2020 | - | $55.79 M(>+9900.0%) | $55.81 M(>+9900.0%) |
| Dec 2019 | $14.00 K(-99.9%) | $4000.00(-33.3%) | $14.00 K(+40.0%) |
| Sep 2019 | - | $6000.00(+50.0%) | $10.00 K(+150.0%) |
| Jun 2019 | - | $4000.00(>+9900.0%) | $4000.00(>+9900.0%) |
| Mar 2019 | - | $0.00 | $0.00 |
| Dec 2018 | $11.46 M | - | - |
FAQ
- What is Keros Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Keros Therapeutics?
- What is Keros Therapeutics annual CFF year-on-year change?
- What is Keros Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Keros Therapeutics?
- What is Keros Therapeutics quarterly CFF year-on-year change?
- What is Keros Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Keros Therapeutics?
- What is Keros Therapeutics TTM CFF year-on-year change?
What is Keros Therapeutics annual cash flow from financing activities?
The current annual CFF of KROS is $391.82 M
What is the all time high annual CFF for Keros Therapeutics?
Keros Therapeutics all-time high annual cash flow from financing activities is $391.82 M
What is Keros Therapeutics annual CFF year-on-year change?
Over the past year, KROS annual cash flow from financing activities has changed by +$212.87 M (+118.95%)
What is Keros Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of KROS is $75.54 M
What is the all time high quarterly CFF for Keros Therapeutics?
Keros Therapeutics all-time high quarterly cash flow from financing activities is $156.80 M
What is Keros Therapeutics quarterly CFF year-on-year change?
Over the past year, KROS quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Keros Therapeutics TTM cash flow from financing activities?
The current TTM CFF of KROS is $391.82 M
What is the all time high TTM CFF for Keros Therapeutics?
Keros Therapeutics all-time high TTM cash flow from financing activities is $391.82 M
What is Keros Therapeutics TTM CFF year-on-year change?
Over the past year, KROS TTM cash flow from financing activities has changed by $0.00 (0.00%)